Searched for:
(1 - 14 of 14)
document
Vogelvang, T.E. (author), Mijatovic, V. (author), Kenemans, P. (author), Emeis, J.J. (author), Heijst, J.A. (author), van der Mooren, M.J. (author), TNO Preventie en Gezondheid (author)
Objective: To investigate the short-term effects of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis. Study design: In a multicenter, 14-week, randomized, placebo-controlled, double-blind, dose-ranging study, healthy postmenopausal women received daily placebo (n = 22), HMR 3339 2.5 mg (n = 25),...
article 2005
document
Giltay, E.J. (author), Gooren, L.J.G. (author), Emeis, J.J. (author), Kooistra, T. (author), Stehouwer, C.D.A. (author), TNO Preventie en Gezondheid (author)
Oral estrogen administration decreases plasma levels of tissue-type plasminogen activator (tPA), which may be explained by a decrease in endothelial tPA synthesis, an increase in its hepatic clearance, or both. In the present study, we determined (1) differences between oral (ie, via the liver) ethinyl estradiol and transdermal (ie, systemic)...
article 2000
document
Lansink, M. (author), Jong, M. (author), Bijsterbosch, M. (author), Bekkers, M. (author), Toet, K. (author), Havekes, L. (author), Emeis, J. (author), Kooistra, T. (author), Gaubius instituut TNO (author)
Several clinical studies have demonstrated an inverse relationship between circulating levels of estrogen and tissue-type plasminogen activator (t-PA). The present study was designed to test the hypothesis that estrogen lower plasma levels of t-PA by increasing its clearance from the bloodstream. 17α-Ethinyl estradiol (EE) treatment resulted in...
article 1999
document
Nieuwenhuys, C.M.A. (author), Béguin, S. (author), Offermans, R.F.G. (author), Emeis, J.J. (author), Hornstra, G. (author), Heemskerk, J.W.M. (author), Gaubius Instituut TNO (author)
We investigated the effects of dietary polyunsaturated fatty acids (PUFAs) on blood lipids and processes that determine hemostatic potential: platelet activation, coagulation, and fibrinolysis. For 8 to 10 weeks, Wistar rats were fed a high-fat diet containing various amounts (2% to 16%) of n-3 PUFAs derived from fish oil (FO) or a diet enriched...
article 1998
document
Kooistra, T. (author), Lansink, M. (author), Emeis, J.J. (author), TNO Preventie en Gezondheid (author)
Chemicals/CAS: 4 [2 (5,6,7,8 tetrahydro 5,5,8,8 tetramethyl 2 naphthyl) 1 propenyl]benzoic acid, 71441-28-6; butyric acid, 107-92-6, 156-54-7, 461-55-2; cyclic AMP, 60-92-4; protein kinase C, 141436-78-4; retinoic acid, 302-79-4; tissue plasminogen activator, 105913-11-9; trichostatin A, 58880-19-6
article 1996
document
Kooistra, T. (author), Schrauwen, Y. (author), Arts, J. (author), Emeis, J.J. (author), Gaubius Instituut TNO (author)
The fibrinolytic activity of blood is to a large extent determined by the plasma level of tissue-type plasminogen activator (t-PA). Changes in the plasma level of t-PA are mainly achieved by the endothelium by two mechanisms: (a) a rapid, short-term release of t-PA, which occurs within minutes (acute release, regulated secretion) and (b) a long...
article 1994
document
Emeis, J.J. (author), van den Hoogen, C.M. (author), Gaubius Laboratory IVVO-TNO, P.O. Box 430, 2300 AK Leiden, Netherlands Instituut voor verouderings- en vaatziekten onderzoek TNO (author)
Pharmacological modulation of the in vivo induction of plasminogen activator inhibitor type-1 (PAI-1) synthesis was studied in rats using the induction of PAI-1 by endotoxin as a model system. Both the cyclooxygenase inhibitors acetylsalicylic acid and indomethacin enhanced PAI-1 induction. The combined cyclooxygenase-lipoxygenase inhibitor,...
article 1992
document
Emeis, J.J. (author), Verheijen, J.H. (author), Instituut voor Verouderings- en Vaatziekten Onderzoek TNO (author)
Chemicals/CAS: Recombinant Proteins; Tissue Plasminogen Activator, EC 3.4.21.68
article 1992
document
Kooistra, T. (author), Opdenberg, J.P. (author), Toet, K. (author), Hendriks, H.F.J. (author), van den Hoogen, R.M. (author), Emeis, J.J. (author), Gaubius Instituut TNO (author)
Tissue-type plasminogen activator (t-PA) and its inhibitor, plasminogen activator inhibitor 1 (PAI-1), play an important role in regulating the fibrinolytic capacity of plasma. Both t-PA and PAI-1 are synthesized by the endothelium. We report that retinoic acid (vitamin A acid) and other retinoids rather specifically stimulate the production of...
article 1991
document
Tranquille, N. (author), Emeis, J.J. (author), Gaubius Instituut TNO (author)
The acute release of tissue-type plasminogen activator (t-PA) was studied in perfused rat hindlegs. Pretreatment of rats with the protein synthesis inhibitor cycloheximide (2 mg/kg) at 1, 3 or 5 h prior to perfusion of rat hindlegs did not influence the amount of t-PA released by platelet-activating factor (20 nM) or bradykinin (1 μM). The...
article 1989
document
Emeis, J.J. (author), van Houwelingen, A.C. (author), van den Hoogen, C.M. (author), Hornstra, G. (author), Gaubius Institute TNO, 2300 AP Leiden, Netherlands (author)
For a period of 6 weeks, 76 healthy male volunteers consumed during their daily main meal the contents of one tin (~ 135 g) of either fish (mackerel) paste or meat paste. Fibrinolytic parameters were determined in plasma samples obtained at the beginning and at the end of the experimental period. No changes were found in plasminogen, α2...
article 1989
document
Emeis, J.J. (author), Edgell, C.J.S. (author), Gaubius instituut TNO (author)
The fibrinolytic characteristics of the endothelial hybrid cell line EA.hy 926, established by fusing a human umbilical vein endothelial cell with a human carcinoma cell line, were studied. The hybrid cell line produced large amounts of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1, and a small amount of...
article 1988
document
Emeis, J.J. (author), Kluft, C. (author), Gaubius instituut TNO (author)
Platelet-activating factor (PAF-acether; 1-O-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) induced the release of plasminogen activator in rat, both in vivo and in perfused hind legs. The released plasminogen activator was shown by immunologic and functional criteria to be tissue-type plasminogen activator (t-PA). Release of t-PA by PAF...
article 1985
document
van der Sande, J.J. (author), Emeis, J.J. (author), Lindeman, J. (author), Gezondheidsorganisatie TNO Gaubius Instituut TNO (author)
Fibrin microthrombi were demonstrated by an immunoenzymehistochemical method in the small blood vessels of the lung and, to a lesser extent, in the brain in rats after minor experimental head injury. It was concluded that intravascular coagulation is a common phenomenon in head injury.
article 1981
Searched for:
(1 - 14 of 14)